Aminoglycoside nephrotoxicity: comparative assessment in critically ill patients

Area of Science:

• Nephrology
• Pharmacology
• Infectious Diseases

Background:

• Aminoglycoside antibiotics are crucial for treating severe bacterial infections.
• Nephrotoxicity is a known adverse effect of aminoglycosides, necessitating comparative safety data.
• Understanding the incidence of kidney damage is vital for optimizing patient care in intensive care units.

Purpose of the Study:

• To prospectively determine and compare the incidence of nephrotoxicity associated with intravenous gentamicin, tobramycin, and amikacin.
• To evaluate the comparative safety profiles of these three commonly used aminoglycoside antibiotics.
• To identify potential differences in kidney toxicity among aminoglycosides in critically ill patients.

Main Methods:

• A prospective trial involving adult intensive care unit patients with bacterial infections.
• Patients received intravenous gentamicin, tobramycin, or amikacin.
• Careful monitoring for nephrotoxicity was conducted, with treatment groups matched for key demographic and clinical variables.

Main Results:

• Nephrotoxicity occurred in 36.3% of gentamicin courses, 22.8% of tobramycin courses, and 25.0% of amikacin courses.
• Tobramycin demonstrated significantly lower nephrotoxicity rates compared to gentamicin (p < 0.05).
• Observed nephrotoxicity was reversible upon cessation of aminoglycoside therapy.

Conclusions:

• Tobramycin appears to be a safer alternative to gentamicin regarding nephrotoxicity in intensive care settings.
• Lower tissue accumulation of tobramycin may contribute to its reduced kidney toxicity.
• These findings support informed antibiotic selection to minimize adverse events in critically ill patients.